Literature DB >> 16293882

Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim.

Muhammad Arshad1, Karen Seiter, Jaroslaw Bilaniuk, Anila Qureshi, Asawari Patil, Gita Ramaswamy, Delong Liu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16293882     DOI： 10.1200/JCO.2005.04.1012

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Diagnosis and management of chronic myelomonocytic leukemia.

Authors:  Francesco Onida; Miloslav Beran
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

2.  Unilateral lymphadenopathy due to the use of granulocyte colony stimulating factor.

Authors:  Ning Zhang; Jie Min; Feng Xiao Huang; Fei Lan; Lili Liu; Helong Zhang
Journal:  BMJ Case Rep       Date:  2011-09-28

Review 3.  Splenic rupture following lenograstim in post-autologous stem cell transplantation treated with emergency open splenectomy: a case report and literature review.

Authors:  Uros Markovic; Cristina Colarossi; Antonio Iuppa; Paola Scire; Ausilia Gorgone; Federica Galbo; Gabriella Amato; Gaetano Moschetti
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

4.  Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.

Authors:  Matteo Lambertini; Paolo Bruzzi; Francesca Poggio; Simona Pastorino; Giovanni Gardin; Matteo Clavarezza; Claudia Bighin; Paolo Pronzato; Lucia Del Mastro
Journal:  Support Care Cancer       Date:  2015-08-27       Impact factor: 3.603

Review 5.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

6.  Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis.

Authors:  Paola Mancino; Katia Falasca; Claudio Ucciferri; Eligio Pizzigallo; Jacopo Vecchiet
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-03-31       Impact factor: 2.576

7.  Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.

Authors:  Kentaro Yamao; Mamoru Takenaka; Tomoe Yoshikawa; Rei Ishikawa; Ayana Okamoto; Tomohiro Yamazaki; Atsushi Nakai; Shunsuke Omoto; Ken Kamata; Kosuke Minaga; Satoru Hagiwara; Toshiharu Sakurai; Naoshi Nishida; Yasutaka Chiba; Tomohiro Watanabe; Masatoshi Kudo
Journal:  Intern Med       Date:  2019-04-17       Impact factor: 1.271

8.  G-CSF shifts erythropoiesis from bone marrow into spleen in the setting of systemic inflammation.

Authors:  Weiqiang Jing; Xing Guo; Fei Qin; Yue Li; Ganyu Wang; Yuxuan Bi; Xing Jin; Lihui Han; Xiaoyuan Dong; Yunxue Zhao
Journal:  Life Sci Alliance       Date:  2020-11-24

Review 9.  613 cases of splenic rupture without risk factors or previously diagnosed disease: a systematic review.

Authors:  F Kris Aubrey-Bassler; Nicholas Sowers
Journal:  BMC Emerg Med       Date:  2012-08-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.